Skip to main content
Premium Trial:

Request an Annual Quote

Genewiz, BeiGene Collaborate on Cancer Biomarker Discovery

NEW YORK (GenomeWeb News) – Genewiz today announced a deal with BeiGene for the use of Genewiz's cancer panels to accelerate cancer biomarker discovery.

Under the terms of the deal, Beijing-based BeiGene will use Genewiz's OncoGxOne Discovery cancer panels to identify and elucidate genetic variations in cancers that are prevalent in China and the Asia-Pacific region.

Financial and other terms of the deal were not disclosed.

"Our collaboration with Genewiz and application of the OncoGxOne(TM) cancer panels will enable characterization of primary tumor models at the genetic level, with a focus on aberrations in cancer related genes," Lai Wang, head of Discovery Biomarkers for BeiGene, said in a statement. BeiGene is a life science biotech firm focused on developing oncology drugs.

The deal is the second by South Plainfield, N.J.-based Genewiz in recent weeks aimed at the Chinese market. In late June it and KeyTest Diagnostics announced a collaboration to develop molecular diagnostics for that market.

Also, Genewiz and the John Theurer Cancer Center at Hackensack University Medical Center last month said they were collaborating on discovering ovarian cancer biomarkers.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.